1. Targeted selected reaction monitoring mass spectrometric immunoassay for insulin-like growth factor 1.
- Author
-
Eric E Niederkofler, David A Phillips, Bryan Krastins, Vathany Kulasingam, Urban A Kiernan, Kemmons A Tubbs, Scott M Peterman, Amol Prakash, Eleftherios P Diamandis, Mary F Lopez, and Dobrin Nedelkov
- Subjects
Medicine ,Science - Abstract
Insulin-like growth factor 1 (IGF1) is an important biomarker of human growth disorders that is routinely analyzed in clinical laboratories. Mass spectrometry-based workflows offer a viable alternative to standard IGF1 immunoassays, which utilize various pre-analytical preparation strategies. In this work we developed an assay that incorporates a novel sample preparation method for dissociating IGF1 from its binding proteins. The workflow also includes an immunoaffinity step using antibody-derivatized pipette tips, followed by elution, trypsin digestion, and LC-MS/MS separation and detection of the signature peptides in a selected reaction monitoring (SRM) mode. The resulting quantitative mass spectrometric immunoassay (MSIA) exhibited good linearity in the range of 1 to 1,500 ng/mL IGF1, intra- and inter-assay precision with CVs of less than 10%, and lowest limits of detection of 1 ng/mL. The linearity and recovery characteristics of the assay were also established, and the new method compared to a commercially available immunoassay using a large cohort of human serum samples. The IGF1 SRM MSIA is well suited for use in clinical laboratories.
- Published
- 2013
- Full Text
- View/download PDF